Ara
Toplam kayıt 36, listelenen: 31-36
Firmicutes/Bacteroidetes Ratio in the Gut Microbiota and IL-1?, IL-6, IL-8, TLR2, TLR4, TLR5 Gene Expressions in Type 2 Diabetes
(Verlag Klinisches Labor GmbH, 2022)
Background: The aim of this study was to determine the Firmicutes/Bacteroidetes ratio in the gut microbiota and IL-1?, IL-6, IL-8, TLR2, TLR4 and TLR5 gene expression levels in the blood of adult type 2 diabetes (T2D) ...
Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
(Turkiye Klinikleri, 2022)
Background/aim: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in ...
ASSESSMENT OF THE RELATIONSHIP BETWEEN PREDIABETES AND LOW MUSCLE MASS BASED ON BLOOD CREATININE LEVEL
(Russian Association of Endocrinologists, 2022)
BACKGROUND: Low muscle mass increases the risk of developing type 2 diabetes mellitus (DM 2) and prediabetes. Nutrition is an important factor in the study of the relationship between low muscle mass and the development ...
Effect of Direct-acting Oral Anticoagulants and Warfarin on Hospital Outcomes in Upper Gastrointestinal Bleeding
(College of Physicians and Surgeons Pakistan, 2022)
Objective: To evaluate the comparison of direct-acting oral anticoagulants (DOACs) and warfarin for their effects on major bleeding and hospital outcomes in patients with acute nonvariceal upper gastrointestinal bleeding ...
Visceral to subcutaneous fat ratio predicts short-term mortality in patients with Covid 19. A multicenter study
(British Institute of Radiology, 2023)
Objective: To evaluate the association of body composition parameters with outcomes in Covid-19. Methods: 173 patients hospitalized for Covid-19 infection in 6 European centers were included in this retrospective study. ...
Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
(Turkish Neuropsychiatric Society, 2023)
Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of ...